Switch to:
Also traded in: Argentina, Germany, Mexico, Sweden, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.20
AZN's Cash-to-Debt is ranked lower than
83% of the 886 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.53 vs. AZN: 0.20 )
Ranked among companies with meaningful Cash-to-Debt only.
AZN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.97 Max: 10.55
Current: 0.2
0.1
10.55
Equity-to-Asset 0.20
AZN's Equity-to-Asset is ranked lower than
91% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. AZN: 0.20 )
Ranked among companies with meaningful Equity-to-Asset only.
AZN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.2  Med: 0.43 Max: 0.59
Current: 0.2
0.2
0.59
Debt-to-Equity 1.54
AZN's Debt-to-Equity is ranked lower than
87% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. AZN: 1.54 )
Ranked among companies with meaningful Debt-to-Equity only.
AZN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03  Med: 0.44 Max: 1.54
Current: 1.54
0.03
1.54
Debt-to-EBITDA 3.26
AZN's Debt-to-EBITDA is ranked lower than
61% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. AZN: 3.26 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AZN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.09  Med: 1.11 Max: 3.26
Current: 3.26
0.09
3.26
Interest Coverage 2.81
AZN's Interest Coverage is ranked lower than
89% of the 683 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 132.39 vs. AZN: 2.81 )
Ranked among companies with meaningful Interest Coverage only.
AZN' s Interest Coverage Range Over the Past 10 Years
Min: 2.81  Med: 6.81 Max: 16.85
Current: 2.81
2.81
16.85
Piotroski F-Score: 4
Altman Z-Score: 1.73
Beneish M-Score: -3.54
WACC vs ROIC
7.00%
9.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 9.24
AZN's Operating Margin % is ranked higher than
73% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.96 vs. AZN: 9.24 )
Ranked among companies with meaningful Operating Margin % only.
AZN' s Operating Margin % Range Over the Past 10 Years
Min: 9  Med: 20.6 Max: 33.5
Current: 9.24
9
33.5
Net Margin % 12.63
AZN's Net Margin % is ranked higher than
73% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. AZN: 12.63 )
Ranked among companies with meaningful Net Margin % only.
AZN' s Net Margin % Range Over the Past 10 Years
Min: 4.64  Med: 17.26 Max: 29.72
Current: 12.63
4.64
29.72
ROE % 20.25
AZN's ROE % is ranked higher than
85% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.75 vs. AZN: 20.25 )
Ranked among companies with meaningful ROE % only.
AZN' s ROE % Range Over the Past 10 Years
Min: 5.9  Med: 24.61 Max: 45.52
Current: 20.25
5.9
45.52
ROA % 4.35
AZN's ROA % is ranked higher than
55% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.29 vs. AZN: 4.35 )
Ranked among companies with meaningful ROA % only.
AZN' s ROA % Range Over the Past 10 Years
Min: 2.2  Med: 8.87 Max: 18.34
Current: 4.35
2.2
18.34
ROC (Joel Greenblatt) % 36.99
AZN's ROC (Joel Greenblatt) % is ranked higher than
88% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.64 vs. AZN: 36.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AZN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 30.35  Med: 97.55 Max: 199.64
Current: 36.99
30.35
199.64
3-Year Revenue Growth Rate -0.50
AZN's 3-Year Revenue Growth Rate is ranked lower than
70% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. AZN: -0.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AZN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.8  Med: 0.7 Max: 25.5
Current: -0.5
-9.8
25.5
3-Year EBITDA Growth Rate 11.40
AZN's 3-Year EBITDA Growth Rate is ranked higher than
62% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.90 vs. AZN: 11.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AZN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 7.5 Max: 28.2
Current: 11.4
-30.1
28.2
3-Year EPS without NRI Growth Rate 41.30
AZN's 3-Year EPS without NRI Growth Rate is ranked higher than
85% of the 657 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. AZN: 41.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AZN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: 17.4 Max: 48.5
Current: 41.3
-48.9
48.5
GuruFocus has detected 9 Warning Signs with AstraZeneca PLC AZN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AZN's 30-Y Financials

Financials (Next Earnings Date: 2018-07-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

AZN Guru Trades in Q2 2017

Jim Simons 130,700 sh (New)
Steven Cohen 603,108 sh (New)
David Dreman 180 sh (New)
Ken Fisher 11,081,856 sh (+476.85%)
PRIMECAP Management 37,900,350 sh (+10.46%)
Pioneer Investments 1,199,570 sh (+1.16%)
Murray Stahl 28,537 sh (+0.83%)
John Hussman 2,000 sh (unchged)
Dodge & Cox 56,669,449 sh (-0.42%)
Charles Brandes 231,588 sh (-2.19%)
NWQ Managers 495,175 sh (-30.35%)
Sarah Ketterer 414,856 sh (-43.56%)
» More
Q3 2017

AZN Guru Trades in Q3 2017

Jeremy Grantham 18,800 sh (New)
Steven Cohen 1,224,939 sh (+103.10%)
Sarah Ketterer 777,457 sh (+87.40%)
NWQ Managers 577,875 sh (+16.70%)
PRIMECAP Management 43,435,530 sh (+14.60%)
Murray Stahl 31,245 sh (+9.49%)
Ken Fisher 11,601,573 sh (+4.69%)
Charles Brandes 241,197 sh (+4.15%)
John Hussman 2,000 sh (unchged)
David Dreman 180 sh (unchged)
Jim Simons Sold Out
Pioneer Investments 1,194,759 sh (-0.40%)
Dodge & Cox 56,200,178 sh (-0.83%)
» More
Q4 2017

AZN Guru Trades in Q4 2017

Jim Simons 103,900 sh (New)
Jeremy Grantham 33,000 sh (+75.53%)
PRIMECAP Management 46,012,634 sh (+5.93%)
Sarah Ketterer 814,117 sh (+4.72%)
NWQ Managers 595,499 sh (+3.05%)
Ken Fisher 11,917,332 sh (+2.72%)
Dodge & Cox 56,530,979 sh (+0.59%)
David Dreman 180 sh (unchged)
John Hussman Sold Out
Charles Brandes Sold Out
Murray Stahl 31,083 sh (-0.52%)
Pioneer Investments 1,170,419 sh (-2.04%)
Steven Cohen 925,200 sh (-24.47%)
» More
Q1 2018

AZN Guru Trades in Q1 2018

Jim Simons 1,031,000 sh (+892.30%)
Steven Cohen 2,905,535 sh (+214.04%)
PRIMECAP Management 51,565,438 sh (+12.07%)
Sarah Ketterer 879,880 sh (+8.08%)
Ken Fisher 12,544,159 sh (+5.26%)
NWQ Managers 600,197 sh (+0.79%)
David Dreman 180 sh (unchged)
Pioneer Investments 1,165,717 sh (-0.40%)
Murray Stahl 30,483 sh (-1.93%)
Dodge & Cox 54,530,179 sh (-3.54%)
Jeremy Grantham 29,200 sh (-11.52%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2018-03-31 Reduce -3.54%0.05%$32.97 - $36.63 $ 36.415%54,530,179
Ken Fisher 2018-03-31 Add 5.26%0.03%$32.97 - $36.63 $ 36.415%12,544,159
NWQ Managers 2018-03-31 Add 0.79%$32.97 - $36.63 $ 36.415%600,197
Dodge & Cox 2017-12-31 Add 0.59%0.01%$32.09 - $34.78 $ 36.418%56,530,979
Ken Fisher 2017-12-31 Add 2.72%0.01%$32.09 - $34.78 $ 36.418%11,917,332
NWQ Managers 2017-12-31 Add 3.05%0.01%$32.09 - $34.78 $ 36.418%595,499
Charles Brandes 2017-12-31 Sold Out 0.17%$32.09 - $34.78 $ 36.418%0
Dodge & Cox 2017-09-30 Reduce -0.83%0.01%$28.88 - $34.16 $ 36.4115%56,200,178
Ken Fisher 2017-09-30 Add 4.69%0.03%$28.88 - $34.16 $ 36.4115%11,601,573
NWQ Managers 2017-09-30 Add 16.70%0.04%$28.88 - $34.16 $ 36.4115%577,875
Charles Brandes 2017-09-30 Add 4.15%0.01%$28.88 - $34.16 $ 36.4115%241,197
Dodge & Cox 2017-06-30 Reduce -0.42%0.01%$29.76 - $35.36 $ 36.4112%56,669,449
Ken Fisher 2017-06-30 Add 476.85%0.5%$29.76 - $35.36 $ 36.4112%11,081,856
NWQ Managers 2017-06-30 Reduce -30.35%0.09%$29.76 - $35.36 $ 36.4112%495,175
Charles Brandes 2017-06-30 Reduce -2.19%$29.76 - $35.36 $ 36.4112%231,588
David Dreman 2017-06-30 New Buy$29.76 - $35.36 $ 36.4112%180
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:LLY, NYSE:BMY, XPAR:SAN, LSE:GSK, XTER:BAYN, TSE:4503, TSE:4519, TSE:4578, NYSE:ABBV, TSE:4568, NYSE:MRK, HKSE:01093, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867, SZSE:002422, MIL:REC, BOM:500087, BOM:500302 » details
Traded in other countries:AZN.Argentina, ZEG.Germany, AZNN.Mexico, AZN.Sweden, AZN.Switzerland, AZN.UK, AZNCF.USA,
Headquarter Location:UK
AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience.

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology, and neuroscience. The majority of sales come from international markets with the United States representing close to 30% of its sales.

Guru Investment Theses on AstraZeneca PLC

Dodge & Cox Funds Comments on AstraZeneca - Aug 01, 2017

AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatments for cancer, respiratory illnesses, cardiovascular problems, and infectious diseases. In the second half of 2016, the share price was under pressure due to concerns about recent and upcoming patent expirations for several of its major drugs. Despite this headwind, we added to the Fund’s holding in early 2017 after reaffirming our investment thesis.



The company’s long -term growth outlook is favorable given its robust new drug pipeline, particularly in oncology (cancer treatment). AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease-fighting capabilities of the body’s immune system to attack cancerous tumors. We have conducted extensive due diligence, which included industry conferences and management meetings, and we continue to believe the immuno-oncology (IO) field holds great promise. Since the IO market is in its very early stages, sponsors and the scientific community are



investing heavily into understanding which tumors can be targeted with IO and which patients will be most responsive to IO treatments (i.e., biomarkers). We think the field will evolve rapidly over the next five to ten years as physicians develop a better understanding of how these drugs work, creating a massive revenue and profit opportunity. With a 4.3% dividend yield, the current valuation is reasonable at 17 times forward earnings and does not appear to reflect potential success from the immunotherapy drug pipeline. AstraZeneca shares represented 1.9% of the Fund on June 30.



From Dodge & Cox Stock Funds second quarter 2017 shareholder letter.



Check out Dodge & Cox latest stock trades

Dodge & Cox Comments on AstraZeneca - Feb 06, 2017

AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatment for cancer and respiratory, cardiovascular, and infectious diseases. The share price has been under pressure due to recent and upcoming patent expirations for major drugs. Despite this headwind, the long-term growth outlook is favorable because of the company’s robust new drug pipeline, particularly in oncology. AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease -fighting capabilities of the body’s immune system to reduce and potentially eliminate cancer tumors. With a 4.6% dividend yield, the current valuation is reasonable and does not appear to reflect the potential success of the immunotherapy drug pipeline.





From Dodge & Cox's Global Stock Fund 4th quarter 2016 shareholder letter.



Check out Dodge & Cox latest stock trades

Top Ranked Articles about AstraZeneca PLC

New Research: Key Drivers of Growth for Ingersoll-Rand PLC, McEwen Mining, Sociedad Quimica y Minera S.A., AstraZeneca, Worldpay, and Silver Wheaton — Factors of Influence, Major Initiatives and Sustained Production
Seroquel Stepping Stone: How Luye Will Use Seroquel to Expand in Emerging Markets
AstraZeneca and the Revolving Door Biotech is not especially notorious as a revolving door industry, but perhaps investors should take a closer look, specifically at AstraZeneca
At the end of last week, director of the FDA’s Division of Pulmonary, Allergy, and Rheumatology Products Dr. Badrul Chowdhury announced his move to British big pharma firm AstraZeneca PLC (NYSE:AZN) as the new vice president of research and development at its biologics unit. Read more...
Ionis and AstraZeneca Advance New Drug for NASH
Esperion Could Surge If Its Cholesterol Drug Proves Safe Esperion Therapeutics has a potential blockbuster cholesterol drug in Phase III with fewer side effects than statins, but it has to be tested on many more people
Cholesterol-reducing statins may be one of the most prescribed, lucrative and successful drug classes in the world, but many people just can’t tolerate them. They cause muscle pain for many, or myalgia (think induced fibromyalgia) because, while they are meant to target chemical intermediaries of cholesterol synthesis in the liver, they also affect intermediaries that promote muscle cell function. Many patients who need these drugs to survive can’t take them. But only 55% of people keep taking statins after six months. Some of this is due to laziness, but side effects are responsible for about 30% of the stoppages overall. Read more...
Report: Exploring Fundamental Drivers Behind Mobile TeleSystems OJSC, Scorpio Tankers, Magellan Midstream Partners, National Steel, AstraZeneca, and Alibaba Group Holding — New Horizons, Emerging Trends, and Upcoming Developments
8 Stocks NWQ Managers Continues to Buy The firm added to these positions in the past 2 quarters
NWQ Managers (Trades, Portfolio) is a value-oriented money management firm. It invested in the following stocks in both the third and fourth quarters. Read more...
Ionis Licences New Antisense Drug for Kidney Disease to AstraZeneca
3 Stocks Move on Wednesday Intuitive Surgical, Tandem Diabetes rise, AstraZeneca falls
Intuitive Surgical Inc. (NASDAQ:ISRG) gained more than 6% on Wednesday after releasing preliminary fourth-quarter 2017 earnings results at the JPMorgan Healthcare Conference. Read more...
Building a Circle of Competency My journey of building a circle of competency in the pharmaceutical business
In my previous article I shared my favorite quotes from Li Lu on the subject of circle of competency. While those quotes are great, they won’t have any practical value unless we can actually put them into practice. Today I’ll share my journey of building a circle of competency (could very well be a circle of incompetence) in the pharmaceutical business. Read more...

Ratios

vs
industry
vs
history
PE Ratio 32.19
AZN's PE Ratio is ranked higher than
50% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. AZN: 32.19 )
Ranked among companies with meaningful PE Ratio only.
AZN' s PE Ratio Range Over the Past 10 Years
Min: 6.03  Med: 12.36 Max: 99.64
Current: 32.19
6.03
99.64
Forward PE Ratio 21.69
AZN's Forward PE Ratio is ranked higher than
54% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.00 vs. AZN: 21.69 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 32.19
AZN's PE Ratio without NRI is ranked higher than
50% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. AZN: 32.19 )
Ranked among companies with meaningful PE Ratio without NRI only.
AZN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.03  Med: 12.36 Max: 99.64
Current: 32.19
6.03
99.64
Price-to-Owner-Earnings 23.30
AZN's Price-to-Owner-Earnings is ranked higher than
77% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.72 vs. AZN: 23.30 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AZN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.37  Med: 11.72 Max: 45.35
Current: 23.3
5.37
45.35
PB Ratio 7.30
AZN's PB Ratio is ranked lower than
73% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. AZN: 7.30 )
Ranked among companies with meaningful PB Ratio only.
AZN' s PB Ratio Range Over the Past 10 Years
Min: 2.3  Med: 3.82 Max: 7.5
Current: 7.3
2.3
7.5
PS Ratio 4.14
AZN's PS Ratio is ranked lower than
53% of the 784 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. AZN: 4.14 )
Ranked among companies with meaningful PS Ratio only.
AZN' s PS Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.4 Max: 4.18
Current: 4.14
1.61
4.18
Price-to-Free-Cash-Flow 50.33
AZN's Price-to-Free-Cash-Flow is ranked lower than
68% of the 216 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.03 vs. AZN: 50.33 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AZN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.18  Med: 17.08 Max: 179.65
Current: 50.33
6.18
179.65
Price-to-Operating-Cash-Flow 26.91
AZN's Price-to-Operating-Cash-Flow is ranked lower than
58% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.21 vs. AZN: 26.91 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AZN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.35  Med: 8.63 Max: 33.31
Current: 26.91
5.35
33.31
EV-to-EBIT 38.97
AZN's EV-to-EBIT is ranked lower than
63% of the 599 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.78 vs. AZN: 38.97 )
Ranked among companies with meaningful EV-to-EBIT only.
AZN' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.1  Med: 9.3 Max: 64.3
Current: 38.97
4.1
64.3
EV-to-EBITDA 18.42
AZN's EV-to-EBITDA is ranked higher than
61% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.59 vs. AZN: 18.42 )
Ranked among companies with meaningful EV-to-EBITDA only.
AZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.5  Med: 7.2 Max: 21.6
Current: 18.42
3.5
21.6
EV-to-Revenue 4.89
AZN's EV-to-Revenue is ranked lower than
59% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. AZN: 4.89 )
Ranked among companies with meaningful EV-to-Revenue only.
AZN' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 2.55 Max: 4.9
Current: 4.89
1.6
4.9
Shiller PE Ratio 20.15
AZN's Shiller PE Ratio is ranked higher than
83% of the 230 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.11 vs. AZN: 20.15 )
Ranked among companies with meaningful Shiller PE Ratio only.
AZN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 3.54  Med: 5.24 Max: 20.75
Current: 20.15
3.54
20.75
Current Ratio 0.73
AZN's Current Ratio is ranked lower than
94% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. AZN: 0.73 )
Ranked among companies with meaningful Current Ratio only.
AZN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.47 Max: 2.01
Current: 0.73
0.64
2.01
Quick Ratio 0.54
AZN's Quick Ratio is ranked lower than
91% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.02 vs. AZN: 0.54 )
Ranked among companies with meaningful Quick Ratio only.
AZN' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.21 Max: 1.83
Current: 0.54
0.54
1.83
Days Inventory 244.44
AZN's Days Inventory is ranked lower than
88% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.78 vs. AZN: 244.44 )
Ranked among companies with meaningful Days Inventory only.
AZN' s Days Inventory Range Over the Past 10 Years
Min: 88.45  Med: 126.46 Max: 244.44
Current: 244.44
88.45
244.44
Days Sales Outstanding 45.86
AZN's Days Sales Outstanding is ranked higher than
77% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.10 vs. AZN: 45.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
AZN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.99  Med: 71.38 Max: 95.12
Current: 45.86
40.99
95.12
Days Payable 288.80
AZN's Days Payable is ranked higher than
94% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. AZN: 288.80 )
Ranked among companies with meaningful Days Payable only.
AZN' s Days Payable Range Over the Past 10 Years
Min: 128.94  Med: 195.78 Max: 397.09
Current: 288.8
128.94
397.09

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.85
AZN's Dividend Yield % is ranked higher than
89% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. AZN: 3.85 )
Ranked among companies with meaningful Dividend Yield % only.
AZN' s Dividend Yield % Range Over the Past 10 Years
Min: 3.27  Med: 4.6 Max: 6.88
Current: 3.85
3.27
6.88
Dividend Payout Ratio 1.26
AZN's Dividend Payout Ratio is ranked lower than
91% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. AZN: 1.26 )
Ranked among companies with meaningful Dividend Payout Ratio only.
AZN' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.37  Med: 0.78 Max: 2.89
Current: 1.26
0.37
2.89
3-Year Dividend Growth Rate 4.40
AZN's 3-Year Dividend Growth Rate is ranked lower than
56% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. AZN: 4.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
AZN' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 9.2 Max: 41.2
Current: 4.4
0
41.2
Forward Dividend Yield % 3.85
AZN's Forward Dividend Yield % is ranked higher than
89% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. AZN: 3.85 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.80
AZN's 5-Year Yield-on-Cost % is ranked higher than
90% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. AZN: 4.80 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AZN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.08  Med: 5.73 Max: 8.57
Current: 4.8
4.08
8.57
3-Year Average Share Buyback Ratio -0.10
AZN's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. AZN: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AZN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.3  Med: 0.8 Max: 5
Current: -0.1
-23.3
5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.00
AZN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
54% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.58 vs. AZN: 3.00 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AZN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.48  Med: 2.06 Max: 17.21
Current: 3
0.48
17.21
Price-to-Median-PS-Value 1.70
AZN's Price-to-Median-PS-Value is ranked lower than
73% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. AZN: 1.70 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AZN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.6  Med: 1.19 Max: 2.88
Current: 1.7
0.6
2.88
Earnings Yield (Greenblatt) % 2.54
AZN's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. AZN: 2.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AZN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 10.7 Max: 24.3
Current: 2.54
1.6
24.3
Forward Rate of Return (Yacktman) % 0.20
AZN's Forward Rate of Return (Yacktman) % is ranked lower than
65% of the 414 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.53 vs. AZN: 0.20 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AZN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -17.9  Med: 11.05 Max: 26.5
Current: 0.2
-17.9
26.5

More Statistics

Revenue (TTM) (Mil) $22,238.00
EPS (TTM) $ 1.11
Beta0.58
Volatility21.27%
52-Week Range $28.43 - 37.30
Shares Outstanding (Mil)2,533.29 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 22,846 25,212 28,109
EBIT (Mil $) 4,286 5,449 7,909
EBITDA (Mil $) 6,766 7,922 10,741
EPS ($) 1.08 1.23 1.28
EPS without NRI ($) 1.08 1.23 1.28
EPS Growth Rate
(Future 3Y To 5Y Estimate)
2.63%
Dividends per Share ($) 1.42 1.46 1.55

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}